2023 Competition Pharmaceutical manufacturing 
European Pharmaceutical Review
NOVEMBER 14, 2023
Yet these industries have faced disruptions and changes in operating environments, resulting in major challenges to overcome, in addition to a new era of global competition driven by targeted national industrial strategies, according to the ABPI. Combined, these sectors have a turnover of £309 billion, ABPI highlighted.
pharmaphorum
DECEMBER 28, 2022
M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. Due diligence teams will review your pharmaceutical quality system – to verify if it is operational and effective.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Impetus Digital
AUGUST 2, 2024
Looking back at 2023 , AI for drug discovery saw both wins and losses. Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology. In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%.
European Pharmaceutical Review
NOVEMBER 8, 2022
Pharmaceutical manufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions.
Medico Reach
FEBRUARY 8, 2023
The global pharmaceutical manufacturing market stood at USD 405.52 The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing. The paradigm shift towards integrated, intelligent, and data-rich technologies is propelling the growth of medicines manufacturing.
PM360
SEPTEMBER 30, 2024
This article outlines how developers can utilize sustainability initiatives to boost revenue, reduce costs, and advance innovation, ensuring a strategic, long-term, and more sustainable position in today’s competitive landscape.
PM360
APRIL 25, 2023
Although AbbVie’s patent for Humira officially expired in 2016, the legal and regulatory delays paused competition for Humira until 2023. pharmaceutical industry. Financial incentives were explored further in the survey as biosimilars are expected to increase competition, thereby lower cost and increase access.
Expert insights. Personalized for you.
110 
Let's personalize your content